503b regulation impact
Semaglutide 503B Exclusion Crisis For Pharmacies?
The FDA’s 2026 exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulk list will raise pharmacy costs by up to 30 percent. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. 503B